Shunji Nagai, Atsushi Yoshida, Keisuke Kohno, David Altshuler, Mio Nakamura, Kimberly A. Brown, Marwan S. Abouljoud, Dilip Moonka – 31 May 2013 – Lymphocytes play an active role in natural immunity against hepatitis C virus (HCV). We hypothesized that a lower absolute lymphocyte count (ALC) may alter HCV outcome after liver transplantation (LT). The aim of this study was to investigate the impact of peritransplant ALC on HCV recurrence following LT. A total of 289 LT patients between 2005 and 2011 were evaluated.

Shunji Nagai, Atsushi Yoshida, Keisuke Kohno, David Altshuler, Mio Nakamura, Kimberly A. Brown, Marwan S. Abouljoud, Dilip Moonka – 31 May 2013 – Lymphocytes play an active role in natural immunity against hepatitis C virus (HCV). We hypothesized that a lower absolute lymphocyte count (ALC) may alter HCV outcome after liver transplantation (LT). The aim of this study was to investigate the impact of peritransplant ALC on HCV recurrence following LT. A total of 289 LT patients between 2005 and 2011 were evaluated.

Julia Freimuth, Jörg‐Martin Bangen, Daniela Lambertz, Wei Hu, Yulia Alexandrowna Nevzorova, Roland Sonntag, Nikolaus Gassler, Dieter Riethmacher, Christian Trautwein, Christian Liedtke – 31 May 2013 – The cytokine tumor necrosis factor alpha (TNF‐α; TNF) plays a critical role early in liver regeneration following partial hepatectomy (PH). TNF stimulates at least three different pathways leading to nuclear factor kappa B (NF‐κB) activation, apoptosis signaling by way of caspase‐8 (Casp8), and activation of cJun N‐terminal kinases (JNK).

Pascal Lapierre, Kathie Béland, Fernando Alvarez – 31 May 2013

Wen‐Ping Xu, Min Yi, Qian‐Qian Li, Wei‐Ping Zhou, Wen‐Ming Cong, Yuan Yang, Bei‐Fang Ning, Chuan Yin, Zhao‐Wei Huang, Jian Wang, Hui Qian, Cai‐Feng Jiang, Yue‐Xiang Chen, Chun‐Yan Xia, Hong‐Yang Wang, Xin Zhang, Wei‐Fen Xie – 31 May 2013 – MicroRNA 370 (miR‐370) is located within the DLK1/DIO3 imprinting region on human chromosome 14, which has been identified as a cancer‐associated genomic region. However, the role of miR‐370 in malignances remains controversial. Here, we report that miR‐370 was repressed in human hepatocellular carcinoma (HCC) tissues and hepatoma cell lines.

Amir Ahmed Qamar – 31 May 2013

Oliver Waidmann, Bernd Kronenberger, Patrick Scheiermann, Verena Köberle, Heiko Mühl, Albrecht Piiper – 31 May 2013

Koji Miyahara, Kazuhiro Nouso, Yasuhiro Miyake, Shinichiro Nakamura, Shuntaro Obi, Maho Amano, Kazuko Hirose, Shin‐Ichiro Nishimura, Kazuhide Yamamoto – 31 May 2013

Sean P. Cleary, William R. Jeck, Xiaobei Zhao, Kui Chen, Sara R. Selitsky, Gleb L. Savich, Ting‐Xu Tan, Michael C. Wu, Gad Getz, Michael S. Lawrence, Joel S. Parker, Jinyu Li, Scott Powers, Hyeja Kim, Sandra Fischer, Maha Guindi, Anand Ghanekar, Derek Y. Chiang – 31 May 2013 – Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma (HCC). As a prerequisite for individualized cancer treatment, we sought to characterize the landscape of recurrent somatic mutations in HCC.

Jannie Pedersen, Thomas H.R. Carlsen, Jannick Prentoe, Santseharay Ramirez, Tanja B. Jensen, Xavier Forns, Harvey Alter, Steven K.H. Foung, Mansun Law, Judith Gottwein, Nina Weis, Jens Bukh – 31 May 2013 – Immunotherapy and vaccine development for hepatitis C virus (HCV) will depend on broadly reactive neutralizing antibodies (NAbs). However, studies in infectious strain JFH1‐based culture systems expressing patient‐derived Core‐NS2 proteins have suggested neutralization resistance for specific HCV strains, in particular, of genotype 2.